bioRxivCancer BiologyPreprint
HIP IMO Report: Analyzing Phenotypic Properties of Bladder Cancer Using Ordinary Differential Equation (ODE) Models
Abstract
Bladder cancer is composed of proliferative and immunogenic phenotypes, which ultimately play a significant role in the growth of the tumor. By using ordinary differential equation models, this paper models the impact of high and low immunogenic cell populations on non-muscle invasive bladder cancer when treated with and without the Bacillus Calmette-Guerin vaccine. Furthermore, this paper models the impact that the Bacillus Calmette-Guerin vaccine has on inflammatory cytokines, which inhibit the growth of tumors by stimulating an immune response. We focus primarily on how the immunogenicity phenotype impacts population dynamics in non-muscle invasive bladder cancer.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Modeling adaptive therapy in non-muscle invasive bladder cancer
M. C. Ferrall-Fairbanks, G. J. Kimmel, … P. M. Altrock·bioRxiv·Nov 7, 2019
- Using Ordinary Differential Equations to Explore Cancer-Immune Dynamics and Tumor Dormancy
Kathleen P. Wilkie, Philip Hahnfeldt, Lynn Hlatky·bioRxiv·Apr 22, 2016
- Identification of sex differences in tumor-specific T cell infiltration in bladder tumor-bearing mice treated with BCG immunotherapy
M. Rousseau, C. J. O. O'Brien, … M. A. Ingersoll·bioRxiv·Jun 19, 2020
- Increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages associate with poor clinical outcomes in BCG treated non-muscle invasive bladder cancer
B. Ravenscroft, P. Yolmo, … M. Koti·bioRxiv·Oct 19, 2023
- Carcinogen induced expansion of atypical B cells and pre-treatment tumor adjacent tertiary lymphoid structures associate with poor response to BCG in non-muscle invasive bladder cancer
- Divergent Macrophage-Regulated T cell States Determine Response to Bacillus Calmette-Guerin (BCG) in High-Risk Bladder Cancer
Ryan J. Brown, Mairah T. Khan, … Joshua J. Meeks·bioRxiv·Sep 18, 2025